Ridge Augmentation in Atrophic Anterior Maxillary Ridges With a Titanium Reinforced Polytetraflouroethelene Membrane and Anorganic Bovine Bone-Derived Mineral With and Without Particulated Autogenous Bone Chips
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Atrophied Anterior Maxillary Ridges
- Sponsor
- Cairo University
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Amount of bone gain (height and width in mm)
- Last Updated
- 7 years ago
Overview
Brief Summary
Ridge Augmentation in Atrophic Anterior Maxillary Ridges with a Titanium Reinforced Polytetraflouroethelene Membrane and Anorganic Bovine Bone-Derived Mineral in intervention group and Anorganic Bovine Bone-Derived Mineralwith Particulated Autogenous Bone Chips in control group.
CBCT will be done before surgery, immediate after surgery and 6 month to compare the bone gain in mm.
Bone sample will be collected during exposure after 6 month of surgery by trephine bur to assess the bone quality through histo-morphometric analysis in order to determine the size, shape and orientation of the bony trabeculae, the size and porosity of the bony cortex in addition to the new bone/ bone substitute ratio
- 1ry outcome: Amount of bone gain will be measured using linear measurements from CBCT immediate after surgery and after 6 month.
- 2ry outcome: a bone sample will be collected and analyzed under histo-morphometric analysis.
Investigators
Sherif osama hegazy
principal investigator
Cairo University
Eligibility Criteria
Inclusion Criteria
- •• Patients with atrophied anterior maxillary ridge area.
- •Age: 18 years and older.
- •Both sexes.
- •No intraoral soft and hard tissue pathology.
- •No systemic condition that contraindicate bone augmentation
Exclusion Criteria
- •• Heavy smokers more than 20 cigarettes per day.(32)
- •Patients with systemic disease that may affect normal healing.
- •Psychiatric problems.
- •Disorders to bone augmentation are related to history of radiation therapy to the head and neck neoplasia.
- •Pregnant or nursing women.
- •Patients with uncontrolled diabetes mellitus, rheumatoid arthritis or osteoporosis.
- •Patient with previous history of radiotherapy.
Outcomes
Primary Outcomes
Amount of bone gain (height and width in mm)
Time Frame: 6 months
will be measured using linear measurements from CBCT
Secondary Outcomes
- a bone sample will be collected and analyzed under histo-morphometric analysis. (no of bone cells in cubic mm)(6 months)